Despite these caveats, enthusiasm for p110 isoform-selective inhibitors for the management of PI3K pathway-altered prostate cancer continues, with the hope of maximizing efficacy and minimizing toxicity. This evidence concerns the gene PIK3CB and prostate carcinoma.